{"id":158,"date":"2018-04-23T11:42:22","date_gmt":"2018-04-23T11:42:22","guid":{"rendered":"http:\/\/edren.org\/ren\/?page_id=158"},"modified":"2021-03-11T10:05:28","modified_gmt":"2021-03-11T10:05:28","slug":"hyperlipidaemia","status":"publish","type":"page","link":"https:\/\/edren.org\/ren\/handbook\/unithdbk\/blood-pressure-and-cardiovascular-disease\/hyperlipidaemia\/","title":{"rendered":"Hyperlipidaemia"},"content":{"rendered":"

All stages of renal disease are associated with increased cardiovascular risk. Isolated microalbuminuria increases the risk of a heart attack or stroke by over 60%, while dialysis increases the risk of death from cardiac disease by up to 100 fold.<\/span><\/p>\n

Hyperlipidaemia is common in patients with renal disease. Sub-group analysis of the big statin trials has demonstrated a risk reduction for cardiovascular events in CKD stage 3 patients treated with statins, comparable to non CKD patients. However, intervention studies in dialysis patients have failed to show improved outcomes. There is also limited evidence that lipid lowering may slow the rate of progression of renal disease.<\/span><\/p>\n


\nKDIGO Guidelines for Lipid Lowering<\/p>\n

<\/span><\/strong><\/span><\/h5>\n

In adults aged > 50 years with eGFR <60 ml\/min\/1.73 m2 GFR (categories G3a-G5, but not those who are receiving dialysis or have undergone renal transplantation) treatment with lipid-lowering therapy is recommended by KDIGO irrespective of baseline lipid parameters. <\/span>
\n<\/span>
\n<\/span>In adults aged > 50 years with CKD and eGFR> 60 ml\/min\/1.73 m2 (GFR categories G1-G2), treatment with a statin should be considered.<\/span>
\n<\/span>
\n<\/span>In adults aged 18\u201349 years with any stage of CKD (but not those who are receiving dialysis or have undergone renal transplantation), statin treatment is recommended in people with one or more of the following:<\/span><\/span><\/p>\n